Search PubMed⌕ Search

Biomedical subjects

Y Uzuka

Publications and source records attributed to Y Uzuka.

At least 73 records · Page 4Linked to original sources
PubMed1986

[Results of follow-up studies on prognosis after immunotherapy with bestatin in acute nonlymphocytic leukemia].

We have recently performed a prognostic investigation of a randomized controlled trial with bestatin for acute non-lymphocytic leukemia in adults. Out of 115 patients registered in this study, 101 patients (48 in a bestatin group and 53 in a control group) were evaluated as eligible. The 50% remission duration was 20.4 months for the bestatin group compared with 11.3 months for the control group. Long-term remission rate at 4 years was 36.5% for the bestatin group compared with 24.1% for the control group, and their respective 50% survival time were 33.0 and 18.1 months, while the long-term survival rate at 4 years was 46.0% for the bestatin group compared with 25.5% for the control group. The bestatin group had a longer remission duration and survival time than the control group. The remission duration and survival time in patients under 49 years of age were not different between the groups. However, in patients over 50 years of age, the bestatin group had a significantly longer remission duration and survival time than the control group. Side effects of bestatin were mild and transient. These data suggest the usefulness of bestatin for the treatment of adult acute nonlymphocytic leukemia.

Aclarubicin↗
PubMed1985

THP-ADM in the treatment of acute promyelocytic leukemia.

Three patients, diagnosed as acute promyelocytic leukemia and disseminated intravascular coagulation (DIC), were treated with THP-ADM in combination with heparin and intensive platelet transfusion. Two of the three patients achieved complete remission. The remaining one patient also responded favorably to the therapy and achieved marrow aplasia, and significant improvement of coagulopathy was observed after chemotherapy. However, he suddenly died of intractable congestive cardiac disturbance ten days after the completion of THP-ADM induction therapy. The mechanism of this unique delayed anthracycline-associated cardiotoxicity was discussed.

Adult↗
PubMed1985

Treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating vindesine-prednisolone.

Twenty-three patients with chronic myelogenous leukemia (CML) in terminal transformation were treated with a regimen incorporating vindesine (a new derivative of vinblastine), prednisolone, and additional cytarabine. Of 21 patients in blastic crisis, complete remission (CR) was achieved in 15 (71.4%). All of five patients with lymphoid morphology and ten of 12 with myeloid morphology (83.3%) achieved CR, while none of four with monocytoid morphology achieved CR. Two patients in accelerated phase also attained CR. Our results compare favorably with those of other regimens in this refractory disorder and indicate that the regimens incorporating vindesine, prednisolone, and additional cytarabine may be recommended in the treatment of CML-blastic crisis with both lymphoid and myeloid morphology and accelerated phase of CML as well.

Adult↗
PubMed1985

[SM-108].

The purpose of this paper is to analyze the available data on SM-108 (4-carbamoylimidazolium 5-olate) with respect to its clinical usefulness, optimal method of administration, and side effects. Successful remission induction was achieved in atypical leukemia using low dose SM-108. To analyze the action of SM-108, freshly isolated leukemic cells and cells from human leukemic cell line were cultured in the presence of SM-108. Minimal evidence of differentiation induction was observed. SM-108 in a higher dose, alone or in combination with other drugs was advocated for the treatment of adult ALL. Side effect including myelotoxicity and gastrointestinal toxicity was minimal.

Adult↗
PubMed1985

[Safety and pharmacology of aspoxicillin in healthy volunteers].

Aspoxicillin (ASPC), a new injectable semisynthetic penicillin, was administered to healthy volunteers to elucidate its safety and pharmacokinetics. No abnormalities obviously attributable to ASPC were observed in the examinations covering subjective and objective symptoms, blood pressure, heart rate, respiratory rate, electrocardiogram and body temperature, as well as in hematology, blood chemistry and urinalysis. There were slight increase in LDH (1 case), Al-P (1 case) and blood-glucose levels (2 cases) at 2 or 4 weeks after the administration with intravenous bolus consecutive injection (1 g X 1 or 2/day, 8 to 10 times), but these increases were not considered to be attributable to ASPC. When ASPC was administered by consecutive intravenous bolus injection, there observed no tendency of accumulation of the drug in serum or urine. When 1 g of ASPC was given intramuscular (i.m.), intravenous injection (i.v.) and intravenous drip infusion (d.i.) route, the maximum antibiotic levels in serum reached 25.2 micrograms/ml, 118.2 micrograms/ml and 70.3 micrograms/ml at 0.75 hour, 0.08 hour and 1 hour after the administration, respectively. The biological half-lives of ASPC attained by these 3 different routes were as follows: 1.73 hours (i.m.), 1.65 hours (i.v.) and 1.44 hours (d.i.). In a cross-over test with piperacillin (PIPC), serum levels of ASPC were higher than those of PIPC and half-lives of ASPC were longer. The 8 hours urinary recovery of ASPC was 75.9% after intravenous injection, 74.6% after intramuscular injection and 88.0% after intravenous drip infusion. Most of urinary recovery was excreted within 4 hours after administration regardless of dose levels, frequency of dosing or administration route. Thin layer chromatographic bioautography was conducted with the samples of serum and urine collected from subjects received ASPC. No antibacterial metabolite was observed in the serum obtained 2 hours after administration but a metabolite identified as amoxicillin was detected in a part of urine samples collected after 8 to 10 hours after the injection.

Adult↗
PubMed1984

Simple and small-scale breakdown of yeast.

A simple and small-scale method for the preparation of homogenate from yeast was developed. The principle of this new method involves the shaking of a small amount of yeast-cell suspension with glass beads on a tower-shaped mixer. When this method is used the cells in 1 ml of cell suspension are broken down and 14 samples can be simultaneously processed under controlled conditions. The degree of cell breakdown, the amount of soluble protein liberated from the cells, and the increase in each enzyme activity in prepared homogenate correlated to the shaking time: maximum values were obtained at 20 min. Enzyme activities in the homogenate were equivalent to or higher than that procured with former methods. This new method is applicable to various species of yeasts.

Cell Fractionation↗
PubMed1984

[Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults].

A cooperative randomized controlled study of immunotherapy with bestatin for ANLL in adults was conducted at 16 institutions. After complete remissions were induced and consolidated with combination chemotherapy, patients were randomly allocated into two groups, one with maintenance chemotherapy alone (C) and the other with the same maintenance chemotherapy plus bestatin (B). Out of 115 patients entered in this study, 101 (B): 48, C: 53) were eligible. The 50% remission duration was 20.4 months for B compared with 11.1 months for C, and comparable 50% survivals were 33.3 and 18.9 months respectively. B had significantly longer remission duration and survival time than C. Remission duration and survival time in patients under 49 years of age were not significantly different in both groups. But in patients over 50 years of age B had significantly longer remission duration and survival time than C. Side effects of bestatin were mild and transitional. These data suggest the usefulness of bestatin for the treatment of adult acute non-lymphocytic leukemia.

Acute Disease↗
PubMed1984

[Chemotherapy of chronic myelogenous leukemia in blastic crisis--vindesine, cytosine arabinoside prednisolone combination therapy].

Twenty patients with chronic myelogenous leukemia in terminal transformation were treated with regimen incorporating vindesine, prednisolone and additional cytosine arabinoside. Of the 19 patients in blastic crisis, complete remission was achieved in 13 (68.4%). All four patients with lymphoid morphology, and nine of the eleven patients with myeloid morphology, achieved complete remission (81.8%); the four with monocytoid morphology did not. One patient in accelerated phase also attained complete remission. The present results indicate that the regimen incorporating vindesine-cytosine arabinoside-prednisolone should be treatment of choice in CML-BC with lymphoid morphology and myeloid morphology as well.

Adolescent↗
PubMed1983

Laboratory evaluation of cefmenoxime: a new cephalosporin. In vitro and in vivo antibacterial activities and pharmacokinetic properties.

Cefmenoxime is a new syn-methoxyimino cephalosporin antibiotic derived from cefotiam, which has been proved to be a very effective and useful antibiotic for the treatment of respiratory infections. This bacteriological and pharmacokinetic study was therefore performed in order to evaluate the potency of cefmenoxime in the treatment of respiratory infections. The minimum inhibitory concentrations of cefmenoxime against 179 isolates of respiratory pathogens (Streptococcus pneumoniae 53, Haemophilus influenzae 64, Klebsiella pneumoniae 43, Escherichia coli 9, Enterobacter spp. 10) were less than 0.20 micrograms/ml, and 43 (73%) of 60 Pseudomonas aeruginosa were inhibited by 12.5 micrograms/ml. In vitro antibacterial activity of cefmenoxime was superior to 18 other antibiotics, including cefotiam and cefotaxime tested in this study. Pharmacokinetic studies on tissue distribution in rats, serum levels and urinary excretion in 3 healthy volunteers, and penetration into bronchial secretes of 9 patients with respiratory infections, revealed that cefmenoxime has a higher penetration into the lung and bronchial secretes compared with cefotiam and cefotaxime. In 1 patient with chronic bronchiolitis, the concentration of cefmenoxime in the intra-bronchial secrete reached 12.5 micrograms/ml. From these results, it is concluded that cefmenoxime is a highly potent and useful antibiotic, and may be more effective in the treatment of respiratory infections than many other cephalosporins, including cefazolin, cefotiam and cefotaxime.

Animals↗
PubMed1983

Colony forming ability of bone marrow cells from patients with acute leukemia.

Bone marrow cells from adult patients with acute leukemia were serially cultured using an in vitro agar culture method. Four categories of growth pattern were recognized according to growth characteristics in vitro in previously untreated patients with leukemia. Detailed cytological investigation was performed for the determination of cell morphology and the origin of colonies. In vitro agar culture may be useful for monitoring the remission-relapse status in acute leukemia.

Adolescent↗
PubMed1983

Treatment of the blastic crisis of chronic myelogenous leukemia with the combination of vindesine and prednisolone, and cytosine arabinoside.

Sixteen patients with chronic myelogenous leukemia in blast crisis were classified into three subgroups on the basis of blast cell morphology and a relation to the chemotherapeutic responsiveness was investigated. All of the four patients with lymphoid morphology, and seven of the eight with myeloid morphology (88%) achieved complete remission while none of the four with monocytoid morphology achieved complete remission.

Antineoplastic Agents↗